Idera’s reinvention takes a hit
The company’s lead, tilsotolimod, is meant to turn cold tumours hot, but it was investors who became frosty last week in response to mid-stage clinical results.
The other shoe drops for Pharming
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Shire dodges pricing questions as lanadelumab’s big day nears
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?
Logic defeats Idercryst and Baker Brothers
The much criticised takeover of Idera by Biocryst will not, after all, take place.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.